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AbstrAct
Objective To evaluate variables associated with 
hemoglobin A1c (HbA1c) and weight reduction when 
adding liraglutide to persons with type 2 diabetes treated 
with multiple daily insulin injections (MDI).
Research design and methods This was a reanalysis 
of a previous trial where 124 patients were enrolled 
in a double-blind, placebo-controlled, multicenter 
randomized trial carried out over 24 weeks. 
Predictors for effect on change in HbA1c and weight 
were analyzed within the treatment group and with 
concurrent interaction analyses. Correlation analyses 
for change in HbA1c and weight from baseline to week 
24 were made.
Results The mean age at baseline was 63.7 years, 
64.8% were men, the mean number of insulin 
injections was 4.4 per day, the mean daily insulin dose 
was 105 units and the mean HbA1c was 74.5 mmol/
mol (9.0%). The mean HbA1c and weight reductions 
were 12.3 mmol/mol (1.13%; P<0.001) and 3.8 kg 
(P<0.001) greater in liraglutide than placebo-treated 
persons. There was no significant predictor for greater 
effect on HbA1c that existed in all analyses (univariate, 
multivariate and interaction analyses against controls). 
For a greater weight reduction when adding liraglutide, 
a lower HbA1c level at baseline was a predictor 
(liraglutide group P=0.002, P=0.020 for liraglutide 
group vs placebo). During follow-up in the liraglutide 
group, no significant correlation was found between 
change in weight and change in HbA1c (r=0.09, 
P=0.46), whereas a correlation existed between 
weight and insulin dose reduction (r=0.44, P<0.001).
Conclusion Weight reduction becomes greater when 
adding liraglutide in patients with type 2 diabetes 
treated with MDI who had a lower HbA1c level 
compared with those with a higher HbA1c level. There 
was no correlation between reductions in HbA1c and 
weight when liraglutide was added, that is, different 
patient groups responded with HbA1c and weight 
reductions.
Trial registration number EudraCT nr: 2012-001941-42.
significance of this study
What is already known about this subject?
 ► Predictors for the effect of glucagon-like peptide-1
receptor agonist on HbA1c and weight in individuals
with type 2 diabetes treated with multiple daily
insulin injections (MDI) have not been studied.
 ► Observational studies without control group have
shown that higher baseline HbA1c is associated
with a greater HbA1c reduction in other treatment
groups.
What are the new findings?
 ► This study showed that lower baseline HbA1c
was a predictor of greater weight reduction when
liraglutide was added, both within the liraglutide
group and when liraglutide group was compared
with the placebo group. High HbA1c values did
not predict a greater effect of liraglutide on HbA1c
when compared with the placebo group.
 ► In this study, there was no association between
patients responding with HbA1c reduction and
patients responding with weight reduction.
How might these results change the focus of 
research or clinical practice?
 ► Effects of liraglutide on HbA1c and weight need
to be evaluated separately in patients with MDI
in clinical practice. Hence, our results indicate
that certain patients respond with greater HbA1c
reductions and others with greater weight
reductions. Those with lower HbA1c levels will
decrease more in weight, while those with higher
HbA1c levels likely will benefit more from the
glucose-lowering effect, since it is known that
decreasing from high glycemic levels reduces the
risk for complications more than decreasing from
lower HbA1c levels.
 ► The use of a control group seems to be important, 
since many significant predictors in the liraglutide
group showed a similar effect in the placebo group.
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BaCkgROund
Diabetes is rapidly increasing worldwide. It is estimated 
that in 2030 there will be over 500 million adults with 
diabetes across the world, most with type 2 diabetes.1 
Good glycemic control is crucial to avoid complica-
tions in type 2 diabetes.2–4 The international guidelines 
on treatment of hyperglycemia in type 2 diabetes focus 
on individualizing treatments using combinations of 
the different available treatment options.5 6 The final 
treatment option in the recommendations is multiple 
daily insulin injections (MDI) or basal insulin plus a 
glucagon-like peptide-1 receptor agonist (GLP-1 RA).6 
However, many patients still do not reach glycemic 
targets.7 In the original analysis of these data, we showed 
that the GLP-1 RA liraglutide is effective also as add-on 
therapy to MDI in type 2 diabetes.8 
GLP-1 RAs are injectable incretin hormones that 
enhance glucose-dependent insulin secretion and reduce 
glucagon secretion by influencing beta cells.9 These 
agents also exert their effect by centrally increasing 
feeling of satiety and by slowing gastric emptying.10 This 
has been shown to reduce both HbA1c and body weight.8 
Overall, little is known on predictors for the effect of 
GLP-1 RAs, and in particular predictors for the effect of 
GLP-1 RA in individuals with type 2 diabetes treated with 
MDI have not been studied.
The aim of this study was to evaluate predictors for 
a beneficial effect of liraglutide on HbA1c, weight and 
insulin doses in individuals with type 2 diabetes treated 
with MDI using data from the MDI Liraglutide trial.8 11 We 
also studied correlations between the different outcome 
variables to see if the same patients respond with 
HbA1c reduction and weight reduction.
MeTHOds
The trial was registered in the EudraCT database before 
study start (EudraCT no 2012-001941-42).
Cohort
This study analyzed data from the MDI Liraglutide trial, 
a randomized, controlled, double-blind trial carried 
out at 13 hospitals and 1 primary care unit in Sweden. 
The design and the main results have previously been 
published.8 11 124 individuals with type 2 diabetes who 
were overweight, had poor glycemic control and were 
treated with MDI were included. The main inclusion 
criteria were HbA1c 58–102 mmol/mol (7.5%–11.5%), 
body mass index (BMI) 27.5–45 kg/m2, C-peptide 
≥0.10 nmol/L and treatment with MDI for ≥6 previous 
months, with or without metformin. MDI was defined
as any basal insulin combined with separate meal time
insulin injections to main meals, with at least two meal
time injections per day.
Overall study procedures
Participants were randomized to receive 1.8 mg liraglu-
tide or placebo in addition to insulin therapy for 24 
weeks. After randomization, participants had follow-up 
visits at weeks 6, 12, 18 and 24, where weight, blood pres-
sure and insulin doses were recorded. HbA1c was meas-
ured at each follow-up visit, and more extensive blood 
samples, including blood lipids, proinsulin, C-peptide 
and adiponectin levels, were measured at baseline, week 
12 and week 24. All blood samples were analyzed at the 
central laboratory, Karolinska University Laboratory 
(Stockholm, Sweden). At baseline, week 12 and week 
24, measurements of waist and hip circumference and 
abdominal sagittal diameter were made. Participants also 
completed three separate weeks of masked continuous 
glucose monitoring (CGM), during the run-in period, 
week 12 and before week 24. The CGM system consists 
of a subcutaneous sensor, a wireless transmitter and a 
receiver, and measures glucose continuously for 1 week.12 
When masked, the receiver does not display the glucose 
values, but stores them for downloading.
Liraglutide was added to insulin therapy according 
to an algorithm previously described.11 In short, insulin 
doses were generally not changed, but if blood glucose 
values were on or close to target at fasting or before a 
meal doses were reduced to avoid unnecessary hypogly-
cemia before uptitration of liraglutide or placebo. Insulin 
doses were then increased to original levels or until target 
blood glucose values were obtained according to the 
algorithm.
Predictors for liraglutide effect
To find predictors we evaluated the association between 
baseline variables and the effect of liraglutide on 
HbA1c, weight and total daily insulin dose in two steps. 
We first studied predictors both within the liraglutide 
group and within the placebo group. To understand if 
possible predictors were related to the use of liraglutide 
and not to other study-related causes, we also evaluated 
whether the predictors were significantly stronger in 
the liraglutide group compared with the placebo group 
through interaction analysis. The following baseline 
variables were evaluated as potential predictors: age, 
sex, diabetes duration, HbA1c, BMI, weight, abdominal 
sagittal diameter, waist circumference, waist:hip ratio, 
adiponectin levels, mean and SD of glucose levels meas-
ured by masked CGM, metformin use, fasting C-peptide 
level, fasting proinsulin level, percentage meal time 
insulin, and total daily insulin dose. HbA1c was meas-
ured according to the International Federation of Clin-
ical Chemistry method, and all values were converted to 
per cent according to National Glycosylation Standard 
Program for dual reporting.13 Proinsulin was measured 
with a commercially available ELISA kit from Mercodia 
AB.
Correlations
To investigate whether the participants who had a reduc-
tion in HbA1c also had a weight reduction or reduced 
their total daily insulin doses, we studied the correla-
tion between changes in these variables. Corresponding 
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Table 1 Baseline characteristics of the full analysis set
Variables
Liraglutide
(n=63)
Placebo
(n=59) P value
Age (years) 63.8 (8.2)
66.3 (44.1; 78.0) n=63
63.6 (7.7)
65.0 (38.9; 77.3) n=59
0.88
Female 23 (36.5%) 20 (33.9%) 0.91
HbA1c (IFCC) (mmol/mol) 74.6 (10.8)
73.0 (53.0; 103.0) n=63
74.4 (12.0)
73.0 (54.0; 101.0) n=59
0.92
Diabetes duration (years) 17.3 (7.7)
16.0 (4.0; 40.0) n=63
17.0 (8.2)
16.0 (2.0; 35.0) n=59
0.88
Total daily meal and basal insulin (units) 105.3 (44.9)
100.0 (28.0; 228.0) n=63
105.6 (41.5)
100.0 (42.0; 230.0) n=59
0.97
Meal insulin/total insulin 0.457 (0.121)
0.452 (0.196; 0.750) n=63
0.435 (0.135)
0.439 (0.082; 0.750) n=59
0.34
Metformin users 43 (68.3%) 43 (72.9%) 0.72
Weight (kg) 98.8 (14.1)
100.0 (69.0; 134.9) n=63
99.8 (14.8)
96.0 (72.5; 139.2) n=59
0.70
BMI (kg/m2) 33.7 (4.3)
33.3 (27.3; 44.0) n=63
33.5 (4.0)
33.5 (27.7; 43.0) n=59
0.75
Waist circumference (cm) 116.1 (10.2)
116.0 (95.0; 135.5) n=61
115.7 (10.6)
113.0 (101.0; 144.8) n=57
0.81
Waist:hip ratio 1.03 (0.07)
1.04 (0.82; 1.16) n=60
1.04 (0.06)
1.04 (0.90; 1.22) n=57
0.54
Sagittal abdominal diameter (cm) 27.9 (3.5)
27.5 (20.5; 36.9) n=63
27.8 (3.5)
27.2 (22.0; 36.7) n=58
0.78
CGM SD (mmol/L) 2.98 (0.71)
2.95 (1.64; 4.84) n=62
2.97 (0.79)
2.77 (1.72; 5.80) n=57
0.94
CGM mean (mmol/L) 10.9 (2.3)
10.5 (5.7; 16.6) n=62
10.7 (2.2)
10.0 (6.9; 16.7) n=57
0.56
Fasting C-peptide (nmol/L) 0.651 (0.477)
0.560 (0.090; 3.100) n=63
0.727 (0.494)
0.620 (0.100; 2.600) n=59
0.39
Fasting proinsulin (pmol/L) 18.9 (23.4)
12.0 (3.3; 136.0) n=63
21.4 (22.2)
15.0 (3.3; 99.0) n=58
0.56
Adiponectin (mg/L) 4.47 (2.17)
4.20 (1.70; 11.00) n=63
4.39 (2.21)
3.85 (2.00; 15.00) n=58
0.84
For categorical variables, n (%) is presented.
For continuous variables, mean (SD), median (minimum; maximum) and n are presented.
For comparison between groups, Fisher’s exact test was used for dichotomous variables and Fisher’s non-parametric permutation test was 
used for continuous variables.
BMI, body mass index; CGM, continuous glucose monitoring; HbA1c, hemoglobin A1c; IFCC, International Federation of Clinical Chemistry.
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correlation analyses were performed between change in 
weight and change in insulin doses.
We also summarized the proportion of patients who 
achieved HbA1c reduction and weight reduction at 
week 24 in three categories: (1) weight loss ≥3%, (2) 
HbA1c reduction ≥11 mmol/mol (1% unit); and (3) 
weight loss ≥3% simultaneously as an HbA1c reduc-
tion ≥11 mmol/mol (1% unit).
statistics
For descriptive purposes, data are presented as mean, 
SD, median, minimum and maximum for continuous 
variables, and as n (%) for categorical variables. Baseline 
comparisons of groups are performed with Fisher’s exact 
test for dichotomous variables and Fisher’s non-para-
metric permutation test for continuous variables.
Prediction analyses of change in HbA1c, weight and 
total daily insulin dose were performed using linear 
regression with the baseline variables described as 
predictors in the Predictors for liraglutide effect section, 
analyzed one at a time. Explanatory variables were treat-
ment group and the baseline predictors, including also 
an interaction between treatment and baseline predic-
tors. Statistical tests for the effect of the predictors were 
performed in the liraglutide group only, and tests for 
treatment with predictor interactions were performed 
only for predictors that were significant in the liraglutide 
group at the 5% level. Post-hoc multivariable analyses 
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Figure 1 Change in HbA1c and weight compared with baseline variables for the liraglutide group and the placebo group. 
(A) Change in HbA1c from baseline to week 24 versus baseline fasting proinsulin. (B) Change in HbA1c from baseline to week
24 versus baseline HbA1c. (C) Change in weight from baseline to week 24 versus baseline HbA1c. (D) Change in weight from
baseline to week 24 versus baseline sagittal abdominal diameter. HbA1c, hemoglobin A1c; IFCC, International Federation of
Clinical Chemistry.
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were also performed, including predictors significant at 
the 5% level in the liraglutide group.
Correlations between change in HbA1c and weight, 
between change in weight and total insulin dose, and 
between change in HbA1c and total insulin dose were 
studied with Pearson correlation coefficients.
All statistical tests were performed at 5% significance 
level. All analyses were performed with SAS V.9.4.
ResulTs
Baseline characteristics
Of the 124 participants enrolled in the trial, 122 had at 
least one valid follow-up measurement and were included 
in the full analysis set. 63 persons received liraglutide and 
59 persons received placebo. Baseline characteristics were 
comparable in both groups (table 1). More complete infor-
mation on baseline characteristics has previously been 
published, including information on diabetic complica-
tions.8 The mean age in the cohort was 63.7 years, 64.8% 
were men, the mean number of insulin injections was 4.4 
per day, the mean daily insulin dose was 105 units and 
the mean HbA1c was 74.5 mmol/mol (9.0%).
Overall effects on Hba1c, weight and insulin dose
HbA1c was reduced by 16.9 mmol/mol (1.54%) in 
the liraglutide group, compared with 4.57 mmol/
mol (0.42%) in the placebo group, with a difference 
of −12.3 mmol/mol (95% CI −15.8 to –8.8 (−1.13%, 
95% CI −1.45 to –0.81); P<0.001). Body weight was 
reduced by 3.8 kg in subjects treated with liraglutide, 
but not placebo (+0.0 kg), with a difference of −3.8 kg 
(95% CI −4.9 to –2.8; P<0.001). The total daily insulin 
dose was reduced by 18.1 U with liraglutide and 2.3 
U with placebo, with a difference of −15.8 U (95% CI 
−23.1 to –8.5; P<0.001).8 No severe hypoglycemias 
occurred during follow-up, and there was no difference 
in non-severe symptomatic hypoglycemia <4.0 mmol/L 
between the liraglutide group and the placebo group, 
with a mean of 1.29 and 1.24 events during follow-up, 
respectively.8
Predictors of Hba1c reduction
Possible predictors of change in HbA1c evaluated, with 
regression coefficients and P values, are shown in online 
supplementary table 1.
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Figure 2 (A) Correlation between change in HbA1c and change in weight from baseline to week 24 in the liraglutide group. (B) 
Correlation between change in weight and change in total daily insulin dose from baseline to week 24 in the liraglutide group. 
(C) Correlation between change in HbA1c and change in total daily insulin dose from baseline to week 24 in the liraglutide
group. HbA1c, hemoglobin A1c; IFCC, International Federation of Clinical Chemistry.
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In the liraglutide group the baseline variables HbA1c 
level (P=0.018), mean glucose level measured by masked 
CGM (P=0.012) and proinsulin level (P=0.047) predicted 
the effects on HbA1c, with higher baseline values being 
associated with greater reduction in HbA1c. Comparing 
the effect of these predictors between treatment groups, 
proinsulin remained a significant predictor for change 
in HbA1c (test for treatment with proinsulin interaction 
P=0.026), while the effect of HbA1c and mean CGM 
glucose could not be shown to differ between the two 
treatment groups (P=0.64 and P=0.38, respectively).
The effects of liraglutide and placebo treatments in 
reducing HbA1c in relation to baseline proinsulin and 
HbA1c levels are shown in figure 1A,B. While the effect 
of liraglutide on HbA1c reduction decreased with lower 
proinsulin levels, the effect remained significant over the 
entire range of observed proinsulin levels compared with 
placebo.
Predictors of weight reduction
Possible predictors of change in weight evaluated, 
with regression coefficients and P values, are shown in 
online supplementary table 2.
In the liraglutide group the baseline variables HbA1c 
level (P=0.002), mean glucose level measured by 
masked CGM (P=0.003) and abdominal sagittal diam-
eter (P=0.016) predicted the effects on weight, with 
lower baseline values predicting greater weight reduc-
tion. Comparing the effect of these predictors between 
treatment groups, HbA1c and abdominal sagittal diam-
eter remained significant predictors for change in 
weight (P=0.020 and P=0.004, respectively), while the 
effect of mean CGM glucose could not be shown to 
differ between the two treatment groups (P=0.08).
The change in weight for liraglutide and place-
bo-treated patients in relation to baseline HbA1c 
and baseline abdominal sagittal diameter is shown in 
figure 1C,D. The effect of liraglutide on weight reduc-
tion decreased with higher HbA1c levels and greater 
abdominal sagittal diameter, but remained signifi-
cant compared with placebo up to HbA1c levels of 
92 mmol/mol and baseline sagittal abdominal diam-
eter of 32.5 cm.
Predictors for change in total daily insulin dose
Possible predictors of change in total insulin dose eval-
uated, with regression coefficients and P values, are 
shown in online supplementary table 3.
In the liraglutide group, higher total insulin dose 
(P=0.001) and lower abdominal sagittal diameter 
(P=0.048) at baseline predicted a greater effect in 
reducing total insulin dose. Comparing the effect of 
these predictors between treatment groups, neither 
could be shown to be stronger in the liraglutide group 
than in the placebo group (test for treatment with 
predictor interaction, P=0.50 and P=0.22, respectively).
Post-hoc sensitivity analysis of predictors for change in 
Hba1c, weight and insulin dose
HbA1c, proinsulin and mean glucose level measured by 
masked CGM were evaluated further for prediction of 
change in HbA1c in multivariable analyses. Proinsulin 
did not remain a significant predictor in the liraglu-
tide group when adjusting for HbA1c (P=0.11) or mean 
CGM glucose (P=0.23), although the predictor with 
treatment interaction was on the borderline of signifi-
cance (P=0.06 adjusted for HbA1c and P=0.08 adjusted 
for mean CGM glucose).
Similarly, HbA1c, mean CGM glucose and abdominal 
sagittal diameter were studied in multivariable analyses 
for prediction of change in weight. HbA1c remained a 
significant predictor both within the liraglutide group 
(P=0.003) and compared with placebo (P=0.031) when 
adjusting for abdominal sagittal diameter. The CGM 
mean was excluded from the model due to multicol-
linearity issues arising when simultaneously including 
HbA1c and mean CGM glucose. Abdominal sagittal 
diameter also remained a significant predictor in the lira-
glutide group both when adjusting for HbA1c (P=0.027) 
and CGM mean (P=0.031), and when evaluated versus 
placebo (P=0.005 adjusted for HbA1c, P=0.004 adjusted 
for mean CGM glucose).
Abdominal sagittal diameter, sex and total daily 
insulin dose at baseline were evaluated in multivari-
able analyses for prediction of change in total daily 
insulin dose. Studying the three variables together, all 
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Figure 3 Proportion of patients with HbA1c 
reduction >1% unit (11 mmol/mol), weight loss >3% and 
combination of the two from baseline to week 24. HbA1c, 
hemoglobin A1c.
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remained significant in the liraglutide group (P<0.001 
for abdominal sagittal diameter, P=0.028 for sex and 
P<0.0001 for insulin dose), but only abdominal sagittal 
diameter showed a significant effect compared with 
placebo (P=0.042). Baseline abdominal sagittal diam-
eter did however not show a significant effect when 
liraglutide addition was evaluated versus placebo in 
univariable analyses (P=0.22).
Correlation analyses
There was no significant correlation between change 
in HbA1c from baseline to week 24 and change in 
weight from baseline to week 24 (r=0.09) (figure 2A; 
P=0.46). Reduction in weight from baseline to week 
24 was correlated with reduction in total insulin dose 
from baseline to week 24 (r=0.44) (figure 2B; P<0.001). 
There was no significant correlation between change 
in HbA1c from baseline to week 24 and change in total 
daily insulin dose from baseline to week 24 (r=0.16) 
(figure 2C; P=0.22).
Figure 3 summarizes the proportion of patients who 
achieved HbA1c reduction and weight reduction at week 
24 by treatment group in three categories: (1) weight 
loss ≥3%, (2) HbA1c reduction ≥11 mmol/mol (1% unit); 
and (3) weight loss ≥3% simultaneously as an HbA1c 
reduction ≥11 mmol/mol (1% unit). There were 76% 
individuals in the liraglutide who experienced HbA1c 
reduction of 10.9 mmol/mol (1% unit) and 56% who 
experienced a weight reduction of 3%. There were 44% 
who experienced both of these effects simultaneously.
disCussiOn
To our knowledge, this is the first placebo-controlled 
analysis of predictors of response to GLP-1 receptor 
analog treatment among persons with type 2 diabetes 
with a complex insulin regimen, MDI. While the orig-
inal analysis showed an overall HbA1c and weight reduc-
tion of 12.3 mmol/mol (1.13%) and 3.8 kg in favor of 
liraglutide compared with placebo, the current analysis 
showed that the weight reduction became greater when 
adding liraglutide in patients with lower compared 
with higher baseline HbA1c levels. Moreover, there 
was no correlation between HbA1c and weight reduc-
tions when adding liraglutide, that is, different patient 
groups responded with HbA1c and weight reductions.
Comparison with previous studies
GLP-1 RAs have different effects on the body. The one 
affecting the beta cells to secrete more insulin9 would lead 
to a greater HbA1c reduction, while the one affecting 
feeling of satiety and gastric emptying is believed to be 
responsible for weight reduction.10 It is because of this 
that it is not implausible to imagine that the effects on 
weight and HbA1c are not correlated, as our study shows 
in persons with type 2 diabetes treated with MDI. More-
over, since patients with lower baseline HbA1c reduced 
weight more and there was a tendency for greater HbA1c 
reduction in those with high HbA1c, it may also partly 
explain the fact that effects on HbA1c and weight do not 
correlate. Previous studies have shown similar results with 
liraglutide and dulaglutide in other populations.14 15
Several studies have been performed on predictors of 
GLP-1 RA effect on HbA1c but not in the current popu-
lation of persons with type 2 diabetes treated with MDI. 
Observational and retrospective studies have shown that 
higher baseline HbA1c is associated with a greater HbA1c 
reduction in populations switching from insulin or 
adding GLP-1 RA to current treatment with long-acting 
insulin analogs. These studies are limited by their obser-
vational nature and their lack of placebo controls.14 16
A relatively recent randomized trial evaluated the influ-
ence of baseline factors on effect when adding exenatide, 
another GLP-1 RA, twice daily or placebo to basal insulin. 
They showed that baseline HbA1c did not predict 
HbA1c change, similar to our results. Exenatide partici-
pants with longer diabetes duration and those with lower 
BMI had greater HbA1c reductions.17 An open-label, 
randomized study that compared exenatide once per 
week with insulin glargine showed that higher baseline 
HbA1c predicted higher HbA1c reduction within the 
treatment group.18 In that study, no interaction analyses 
were performed.
In our study we found that a high HbA1c level at base-
line predicted a greater HbA1c reduction in the liraglu-
tide group, but when comparing the same predictor with 
the placebo group the significance did not remain. This 
can likely be explained by the phenomenon regression 
to the mean or study-related causes.19 This illustrates 
the need for a placebo control group when evaluating 
predictors of effects of GLP-RA.
To our knowledge little has been done earlier on eval-
uating the predictors of effect on weight; research has 
rather been focused on HbA1c effect.20–23 The finding 
that lower HbA1c predicts greater weight loss has to 
our knowledge not been described before. This finding 
could possibly be explained by a previous loss of calories 
via leakage of glucose to the urine in those with higher 
HbA1c. When achieving better glycemic control, these 
calories can instead be used and stored.
7BMJ Open Diab Res Care 2018;6:e000464. doi:10.1136/bmjdrc-2017-000464
Clinical Care/Education/Nutrition
Lower abdominal sagittal diameter was a predictor for 
greater weight loss. In the SCALE study on non-diabetic 
participants, those with higher BMI had less effect on 
weight reduction with liraglutide treatment.24 This could 
indicate that the weight loss is dependent on factors asso-
ciated with lower BMI and abdominal sagittal diameter.
There were indications that a higher fasting proinsulin 
level predicted a greater reduction in HbA1c. Fasting 
proinsulin is believed to be related to insulin resistance 
and beta cell dysfunction.25 26 A possible explanation 
for the relation between higher baseline proinsulin 
and potential greater HbA1c reduction is that GLP-1 
RA influences insulin resistance by decreasing visceral 
abdominal fat.22 Moreover, it is also possible that the 
association between proinsulin and HbA1c reduction 
could be explained by GLP-1 RA working by increasing 
the processing of proinsulin to insulin in beta cells, some-
thing that has been shown in mice.27 If this is the case, it 
could be imagined that those with a higher proinsulin 
level, and thus a higher insulin resistance and beta cell 
dysfunction, would have the most effect from GLP-1 RA 
treatment. Further and more basal research is needed to 
confirm these findings.
strengths
A strength of the current study is its double-blinded, 
randomized design. By performing the interaction anal-
ysis as we have done, we take into consideration how the 
liraglutide group and the control group relate to each 
other. This means we can rule out other study-related 
effects or regression to the mean when evaluating predic-
tors.19 We also get an indication if something other than 
the trial arm is influencing the predictive effect.
limitations
The trial is somewhat limited by the small number of 
participants: 122, of whom 63 received liraglutide. We 
cannot make detailed subgroup analyses or complex 
multivariable interaction analyses without losing statis-
tical power. It is therefore possible that additional weak 
predictors would have been detected in a larger patient 
material. Another potential limitation is the relatively 
short duration of 24 weeks, which means we can mainly 
draw conclusions about the predictors for short-term effi-
cacy. However, other studies have shown sustained effects 
of liraglutide over longer periods of time,28 29 so the same 
predictors may apply over longer time periods.
Multiple testing
Due to the exploratory nature of this analysis, it was 
decided to perform all significance tests at 5% level 
without adjustments for multiple testing. However, the 
probability of false discoveries was somewhat reduced by 
the two-step procedure used for evaluation of predictors, 
followed by post-hoc multivariable analyses, as signifi-
cance within the liraglutide group, in interaction analyses 
and in multivariable analyses was required for a predictor 
to be interpreted as significant. Also, all predictors 
evaluated in the prediction analyses were predetermined 
prior to analyzing the data.
implications
Higher HbA1c did not predict a greater HbA1c reduc-
tion in the liraglutide group when comparing with the 
HbA1c change in the placebo group. This suggests that 
this drug should be evaluated as a treatment option not 
only to those with the poorest glycemic control. The fact 
that those with lower HbA1c at baseline had the greatest 
weight reduction suggests the same.
The recommendation for usage of GLP-1 RA is still 
somewhat restricted in national guidelines. For example 
the National Institute for Health and Care Excellence 
in the UK has recommended continued treatment with 
GLP-1 RA only if the patient has lost at least 11 mmol/
mol (1.0%) in HbA1c and 3% of body weight in 6 
months.30 On the contrary, our results suggest that there 
is no correlation between improved glycemic control and 
weight loss during treatment. Our results indicate a need 
to start looking at these efficacy variables separately when 
evaluating the treatment. Substantial weight loss may 
have benefits for the overall health of the patient even 
if glycemic control remains the same.31 At the same time 
improved glycemic control has positive health effects 
even in the absence of weight loss.32
The findings in the current study suggest that fasting 
proinsulin may be a predictor of the beneficial effects of 
liraglutide on HbA1c. This needs to be evaluated in other 
studies to be confirmed. Finding predictors for effective 
therapy is important since it can increase our under-
standing of how the drug acts in an in vivo environment. 
There has been an ongoing discussion why patients seem 
to vary in their response to treatment, and it is essential 
in clinical practice to evaluate the effect on an individual 
basis.
COnClusiOns
Weight reduction was greater when liraglutide was added 
in patients with type 2 diabetes treated with MDI who 
had lower compared with higher HbA1c levels. There 
was no correlation between reductions in HbA1c and 
weight when liraglutide was added, that is, different 
patient groups respond with HbA1c and weight reduc-
tions. Hence, when considering initiating therapy and 
evaluating whether a patient responds to therapy, effects 
on HbA1c and weight must be judged individually. 
A composite effect on HbA1c and weight to define a 
responder should be used with caution.
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